strong cash flow wide moat
updat forecast estim aug
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research aug
estim aug
price data aug
rate updat aug
currenc amount express
valuat growth profit
methodolog valu compani
gilead gener stellar profit margin hiv hcv
portfolio requir small salesforc inexpens
manufactur think firm portfolio pipelin support
wide moat gilead need hcv market stabil strong
continu innov hiv solid pipelin data smart futur
acquisit return growth
gilead tenofovir molecul -- viread truvada older
single-tablet regimen -- histor form heart firm
afford less like miss dose develop
drug resist need make one co-payment older
combo pill atripla first replac gilead complera
stribild better safeti profil newest combo
pill -- replac tdf taf -- reduc bone kidney safeti
issu see rapid uptak gilead biggest competit
threat hiv glaxo triumeq saw rapid growth glaxo
 test novel combin also bypass gilead
biktarvi launch push patent protect
late boost market share
sovaldi harvoni combin sovaldi ledipasvir
peak billion sale howev demand
shrink patient cure competit
merck led sever round signific
price-discount expect gilead current
launch eight-week regimen mavyret share billion-plu
market long term
gilead build pipelin outsid hiv hcv need
acquisit like kite car-t therapi yescarta see
strong growth gilead first cancer drug zydelig launch
limit safeti concern optimist
galapago collabor lead nash program selonsertib
also phase open multi-billion-dollar opportun
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
develop market therapi treat life-threaten
infecti diseas core portfolio focus hiv
hepat acquisit coru pharma myogen cv
therapeut arresto bioscienc calistoga broaden focu
includ pulmonari cardiovascular diseas cancer gilead
acquisit pharmasset brought right hepat drug sovaldi
also part combin drug harvoni kite acquisit boost
gilead exposur cell therapi oncolog
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
valuat growth profit aug
rais gilead fair valu estim
incorpor bullish expect
firm nash pipelin near-term sale yescarta
correct slightli lower tax rate
firm nash pipelin pivot data advanc
fibrosi cirrhosi patient first half
selonsertib well phase data variou combin
regimen second half includ nash
sale gilead peak north billion annual
launch begin
assum billion gilead hcv sale
almost lower patient demand key
headwind follow addit price headwind
next-gener product mavyret
result see gilead hcv revenu billion
assum averag net price around
think gilead hiv/hbv franchis peak billion
 gener competit lead roughli
averag annual headwind begin
assum taf-bas combin regimen biktarvi
genvoya descovi odefsey help off-set declin
gilead could see mid-single-digit patient loss
 annual begin still view stribild
complera gener strong long-term competit
taf-bas regimen particularli outsid
second-lin dlbcl therapi form blood cancer
assum cost capit gilead rate
systemat risk surround gilead share
averag assum cost equiti align
capit cost assumpt return equiti investor
like demand long run also assum
pre-tax cost debt reflect normal
gilead portfolio divers hiv focu
expand exposur hepat cancer market
still think firm warrant medium uncertainti
rate owe volatil hepat market demand
price
bullish scenario expect gilead achiev stronger
convers newer hiv product stronger
hepat price power scenario assum hiv
franchis sale peak billion follow
midteen declin face gener competit
also assum less aggress rebat hepat
 market bull-cas scenario result
billion hepat sale gilead also
use slightli higher earnings-growth rate stage ii
model result fair valu estim
per share
overal forecast averag annual sale declin
non-gaap earn declin sovaldi
lower tax rate led oper margin
shrink revenu think margin
declin assum cost-cut
help off-set margin pressur
includ billion sale yescarta
eventu surpass billion usag expand
pessimist scenario assum complera
stribild next-gener taf-bas regimen like
genvoya biktarvi unabl gain signific share
hiv market lack perceiv efficaci
safeti conveni benefit compar older
regimen glaxo doublet regimen hiv franchis sale
peak billion fall averag
annual owe sever pressur scenario
assum addit price competit hepat
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
tdf molecul present viread truvada
atripla complera stribild said key patent
begin expir europ next-gener product
could struggl provid suffici differenti
reimburs key market put pressur
howev think firm shown translat
extens understand drug discoveri
develop process hiv new therapeut area
allow achiev wide-moat statu despit initi
critic high price gilead paid pharmasset
earli billion acquisit gave gilead
valuabl hepat drug industri also
demonstr firm abil recogn potenti
uniqu natur sovaldi safeti efficaci profil
compar toxic nucleotid analog think
firm experi anoth nucleotid analog tenofovir
key ingredi gilead hiv combin regimen
probabl contribut recognit sovaldi valu
earli stage develop
molecul sovaldi harvoni redefin gilead
powerhous broader infecti diseas market
gilead lead way all-or treatment
hepat market gilead multi-billion-dollar
product think low resist potenti
pan-genotyp efficaci gilead regimen allow
firm retain close global hcv market
long run despit competit merck
product platform reflect grow record recogn
potenti infecti diseas discoveri
foundat hiv drug tenofovir deal brought right
emtricitabin anoth ingredi gilead
combin regimen elvitegravir integras inhibitor
stribild sovaldi gilead oncolog pipelin also
market result less billion hepat
sale gilead also use earnings-growth
rate stage ii model yield
patent protect newer hiv regimen gilead
continu domin hepat market
enough ensur strong return next coupl
decad gilead expertis infecti diseas
single-pil formul part research
develop strategi see one strongest
intang asset support firm wide moat
gilead moat form leadership posit
treatment hiv three patent product form
backbon today treatment regimen despit
numer competitor compani establish
lead market share spectacular profit
conveni effect safe treatment gilead serv
treat hiv patient unit state
manag done excel job maxim sale
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
rather share partner complera
johnson johnson atripla bristol-my squibb
benefit firm return invest capit
gilead also face strong competit hiv still see
gilead best-posit field approv
glaxo integras inhibitor tivicay combin tablet
triumeq epzicom/tivicay led gilead market share
declin glaxo gilead appear
gain share hiv player merck bristol
lack combin pill expect gilead
biktarvi launch glaxo juluca approv
dual-combo lamivudine/tivicay approv
continu domin market
gilead pipelin continu sale hiv beyond first
wave patent expir need counter declin
hcv tough year hcv sale
declin declin estim
roughli declin bring larger hit demand falter
launch next-gener product beyond
assum annual headwind hcv sale
remain forecast period price patient demand
declin rel steadili beyond
grow advanc receiv boost
recent acquisit kite includ car-t cell therapi
yescarta think firm smart acquisit
potenti futur combin regimen hematolog
oncolog immunolog nash diversifi
firm strengthen intang asset howev
think gilead hiv-rel patent exposur price
volum headwind hepat market prevent
moat expand
see grow evid firm acquisit
strategi could serv well oncolog immunolog
follow sever year smaller acquisit
idelalisib via calistoga launch safeti risk
limit usag later line therapi howev
oncolog drug safer dose zydelig combin
therapi still test sever potenti
immunolog indic well yescarta acquir
kite pharma octob launch diffus
larg b-cell lymphoma think gilead histori
smart clinic trial design market expertis could
boost launch speed long-term potenti kite
portfolio addit acquisit arresto nimbu
apollo well licens deal phenex given
gilead sever differ mechan treat nash
potenti combin key data begin read
gilead product biolog firm
vulner gener version mani older hiv
product within five year howev newer hiv regimen
complera stribild saw strong launch genvoya
improv kidney bone safeti profil led fastest
hiv combin pill sale ramp help
differenti drug gener version gilead
truvada atripla stribild genvoya gilead
retain virtual econom behind hiv sale
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
ogilead market sever single-tablet regimen hiv
firm next-gener product better
long-term safeti profil led genvoya biktarvi
boost gilead market share
ogilead hiv franchis see first import
patent expir firm
need convert patient newer product like
genvoya biktarvi avoid signific hit sale
oguidelin aim
improv diagnosi
treatment rate new prophylaxi use provid
strong tailwind growth hiv
owith approv sovaldi harvoni gilead
market leader all-or hepat treatment
none gilead competitor nucleotid
analog make billion acquisit
opric pressur reduc willing pay
conveni could weigh gilead growth atripla
becom formid gener competitor
gilead newer hiv product compet
hepat regimen give pbm abil
ohcv patient demand plummet visibl
long-term demand price low
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
gilead held billion cash billion debt
end gilead continu rais debt rel
low rate assum blend interest rate
includ billion debt term loan
support octob acquisit kite pharma gilead
use cash fund aggress share repurchas
billion rel new dividend gilead hiv
hcv busi also gener stellar cash flow
despit declin hcv sale gilead easili gener
around billion free cash flow annual
expect gilead use cash futur
acquisit particularli tax reform allow repatri
oversea cash note share repurchas
dial back significantli fund dividend growth
acquisit
increas competit price pressur hiv
hepat market risk gilead global price
pressur consolid pharmacy-benefit manag
could reduc gilead abil charg price premium
new drug extend patent protect gilead newest
hiv product perceiv offer improv safeti
efficaci versu older hiv product larg portion
sale foundat could risk patent gilead
top market hiv product expir firm
need see signific switch newer product like
biktarvi counter neg impact gener
competitor estim gilead
purchas higher rebat sale
implement escal overal healthcar cost
tight budget could lead continu elev price
pressur europ gilead also paid
signific premium acquir myogen failur
darusentan put even pressur letairi make
deal accret said billion pharmasset
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
acquisit foundat gilead hcv franchis
allow gilead gener billion hcv
revenu alon howev gilead hcv busi
declin steepli competit allow pharmaci
benefit manag like express script aggress
negoti price gilead appear gain
major contract access patient sacrif
price hiv express script could exclud newer hiv
product formulari safe effect
competit -- like gilead atripla complera -- lose
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
va collegeamerica invmt co america
fidel manag research compani
share
fund
share
fund
assign gilead exemplari mark stewardship base
moat-build invest strategi good alloc
capit superior board
independ
qualif gilead made sever acquisit
collabor deal year support
infecti diseas portfolio exampl acquisit
triangl brought emtriva critic compon
truvada firm single-tablet hiv regimen
outsid gilead therapeut area focu acquisit
cv also wise invest angina
drug ranexa grow strongli addit billion
bet pharmasset -- hepat drug sovaldi --
excel use capit earli judg
billion acquisit kite pharma current
assum deal neutral long-term roic upsid
possibl yescarta uptak faster expect
ceo john milligan step end
along board chairman former ceo john martin
milligan spent year gilead
ceo role sinc march follow chief
scientif offic norbert bischofberg departur
end april think time logic give
firm opportun fresh manag team
enter time massiv revenu headwind
hcv franchis abat milligan martin
insid gilead board
offer divers skill set includ expertis public polici
infecti diseas global health initi like
manag reward progress rather
earn per share gilead decis boost share
repurchas smart one view share
trade fair valu estim much
past three year see blood cancer immunolog
key area futur growth gilead
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
gilead top execut transit continu ceo
gilead report solid second-quart result reflect
underli strength hiv busi stabil
hepat expect make signific
chang per share fair valu estim alongsid
earn announc firm announc ceo
john milligan step end year along
current board chairman former ceo john martin
milligan spent year gilead
ceo role sinc march follow chief
scientif offic norbert bischofberg departur
end april think time logic give
firm opportun fresh manag team enter
time massiv revenu headwind hcv
franchis abat guidanc full year larg
maintain expect make signific
chang valuat model correct
slightli lower tax rate dive deeper potenti
firm nash pipelin pivot data
advanc fibrosi cirrhosi patient first half
selonsertib well phase data variou
combin regimen second half think
firm next-gener hiv therapi stabil hcv
busi potenti growth new area
oncolog cell therapi nash support wide moat
total revenu fell second quarter
billion hiv sale grew billion
partli due slightli higher percentag sale
privat payer higher price point govern
payer also due strong launch new combin
regimen biktarvi saw million sale
first full quarter patient larg switch
older gilead regimen also glaxo triumeq tivicay
glaxo recent report solid data two-drug
combin lamivudin tivicay dolutegravir
treatment-nav patient think biktarvi strong
efficaci safeti profil entrench natur
three-drug regimen allow biktarvi continu
launch strongli hcv revenu fell billion
declin sequenti reflect
environ stabil price market share yescarta
sale million grow steadili launch
continu maintain estim drug
believ potenti broader blood cancer
indic potenti combin checkpoint
trump blueprint lower drug price offer minor
chang pharma biotech moat impact
administr blueprint lower drug price reduc
out-of-pocket cost offer propos dont impact
moat rate pharma industri
price power brand drug still look
transpar provid inform help
patient lower out-of-pocket cost believ
limit impact brand drug price mild
polici propos appear larg build
budget propos drug white paper issu
council econom advisor februari aggreg
think propos would like impact less
drug spend exclud potenti chang
negoti medicar part drug could offer
anoth reduct drug spend depend
exact implement
overal blueprint propos creat minor headwind
brand drug price regard propos increas
gener competit view brand drug
industri tactic
limit gener competit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
rel ineffect gener biolog biosimilar
larg assum swift competit follow patent
loss alreadi line polici effort
increas gener competit hard-to-mak drug
polici propos limit use risk evalu
mitig strategi delay gener competit rare
use could potenti impact drug firm
exampl celgen key drug revlimid could face
addit gener rapid launch gener
review fda
propos increas negoti around part drug
look like substant propos drug
histor face much price pressur note
drug tend least interchang
competit make negoti drug price
difficult polici propos regard incent
lower drug list price price transpar
direct-to-consum ad inform view
limit potenti reduc price lastli
focu lower out-of-pocket drug cost allow
cost-sav inform pharmacist provid
inform lower-cost altern treatment option
medicar patient could provid minor cost save
would significantli alter price power brand
within polici propos beyond immedi
action outlin administr provid
opportun explor addit cost save
granular propos limit view
major addit opportun focus
close rel smaller price loophol explor
altern price model value-bas
reimburs new strategi around medicaid drug
price believ innov brand drug
abl thrive environ major current
brand drug develop alreadi focus
innov meet increas demand privat sector
payer pharmaci benefit manag pbm
addit two opportun explor could
significantli help brand drugmak first propos
limit abil pbm reli rebat drug firm
lower drug cost could forc transpar
upfront price discount potenti give drug firm
power set price second effort make
countri pay drug hold potenti increas
global price power view initi larg
polit driven difficult implement
background polici propos
enact pleas see healthcar observ drug
price reform weigh valuat moat look
secur biotech industri look under-valued
trump drug look modestli lower drug price
keep pharma biotech moat intact may
trump polici speech lower drug price didnt offer
mani specif focus mostli reduc middleman
profit rais drug price oversea base
 govern budget propos council
econom advisor white paper drug polici expect
modest neg headwind brand drug price
continu view moat within pharma/biotech
industri intact support strong price power
patent protect drug view brand drug group
aggreg under-valued expect group digest
modest price headwind major impact
valuat view roch sanofi allergan
under-valued wide moat drug firm
biggest neg seen administr
propos shift medicar part drug part
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
scenario price decreas drug
pharma earn would like fall close
heavier hit firm exposur
drug channel regeneron beyond
polici modestli neg polici propos includ
test new price program medicaid modifi
exclus rule increas gener competit
increas medicar part negoti power
modifi payment structur medicar part
exclud shift part medicar
estim save initi look like less
 drug spend
posit polici propos brand drug
offer well implement seem unlik
notabl demand countri pay drug
seem difficult implement also break
pharmaci benefit manag increas competit would
like give drug compani power drug price
howev either polici implement
would expect major windfal brand drug industri
background polici propos
enact pleas see healthcar observ drug
price reform weigh valuat moat look
secur biotech industri look under-valued within
report highlight impact enact chang
drug payment increas discount
medicar part doughnut hole sale also review
depth drug polici propos council
econom advisor budget
slightli trim gilead fve follow
trim product sale assumpt year
hepat gilead see new competit
hiv/hbv hit viread gener
hbv steeper hiv inventori drawdown market
prepar convers firm latest single-tablet
regimen biktarvi weve slightli lower fair valu
estim per share result howev
share look slightli under-valued think market
undervalu gilead hiv portfolio well oncolog
portfolio immunology/nash pipelin support
firm wide moat expect key pipelin data
nash drug selonsertib immunolog drug filgotinib
ra first half
biktarvi sale million quarter
expect becom gilead largest hiv product
easili reach billion peak biktarvi
approv februari like gain approv
europ third quarter patient appear
switch gilead genvoya cannib gilead hiv
sale also glaxo tivicay triumeq
slightli expand market share roughli
gilead hiv sale volum taf-contain
regimen think bode well firm resili
face on-going gener pressur europ
anticip patent expir
yescarta sale million first quarter
maintain view sale could reach
billion billion peak howev
reimburs take time given inpati
set hospit gilead also ramp
number center author administ drug
novarti compet car-t cell therapi kymriah
approv fda dlbcl think gilead
retain first-mov advantag indic
gilead total product sale fell base
combin hiv/hbv growth signific
declin firm hcv portfolio hiv/hbv growth face
headwind lower inventori manag note
demand remain strong prescript growth
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
quarter hcv expect slightli
pressur addit quarter gain share
price appear stabil non-gaap oper
margin fell roughli percentag point
oper margin first quarter due slightli
lower gross margin attribut partli dramat
lower hcv price well higher sell gener
administr expens firm focus launch
new oncolog therapi yescarta hiv therapi biktarvi
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
